CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $318,000 | +34.2% | 4,200 | +98.4% | 0.01% | +33.3% |
| Q3 2021 | $237,000 | -30.7% | 2,117 | +0.1% | 0.01% | -40.0% |
| Q2 2021 | $342,000 | +165.1% | 2,115 | +37.6% | 0.01% | +66.7% |
| Q3 2020 | $129,000 | -64.6% | 1,537 | -68.9% | 0.01% | -70.0% |
| Q2 2020 | $364,000 | +3.7% | 4,950 | -33.5% | 0.02% | +17.6% |
| Q2 2019 | $351,000 | +17.8% | 7,446 | +46.6% | 0.02% | -10.5% |
| Q2 2018 | $298,000 | -41.5% | 5,078 | -54.4% | 0.02% | -48.6% |
| Q1 2018 | $509,000 | -13.6% | 11,131 | -55.7% | 0.04% | -21.3% |
| Q4 2017 | $589,000 | – | 25,106 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |